Skip to content
HowShorted

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2020

In 2020, ARROWHEAD PHARMACEUTICALS, INC.'s disclosed short interest ran from 11.51% of shares outstanding on 15 Jan 2020 to 5.76% on 31 Dec 2020, a change of -5.75 percentage points. The year's high was 11.51% on 15 Jan 2020 and its low 5.76% on 31 Dec 2020, averaging 8.62% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.02 days on 31 Aug 2020. Full history: ARROWHEAD PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ARROWHEAD PHARMACEUTICALS, INC. in 2020

2020 in figures

Start of year
11.51% (15 Jan 2020)
End of year
5.76% (31 Dec 2020)
Change
-5.75 pp
High
11.51% (15 Jan 2020)
Low
5.76% (31 Dec 2020)
Average
8.62%
Highest days to cover
13.02 (31 Aug 2020)
SEC filings marked
8

Every report in 2020

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202011.51%7.78
31 Jan 202010.47%5.17
14 Feb 20209.37%6.5510-Q filed, results (8-K)
28 Feb 20208.58%5.33
13 Mar 20208.14%5.21
31 Mar 20207.54%3.84
15 Apr 20207.51%7.13
30 Apr 20207.84%7.49
15 May 20207.90%6.8010-Q filed, results (8-K)
29 May 20208.18%8.09
15 Jun 20208.25%9.18
30 Jun 20209.82%7.26
15 Jul 202010.12%10.60
31 Jul 20209.61%12.75
14 Aug 20209.30%11.8910-Q filed, results (8-K)
31 Aug 20209.21%13.02
15 Sep 20208.86%8.13
30 Sep 20208.81%2.56
15 Oct 20209.12%10.76
30 Oct 20208.12%6.14
13 Nov 20208.02%9.50
30 Nov 20207.65%6.3310-K filed, results (8-K)
15 Dec 20207.23%8.67
31 Dec 20205.76%6.12

See also: ARROWHEAD PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.